Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.
Hochmair MJ, Vermaelen K, Mountzios G, Carcereny E, Dooms C, Lee SH, Morocz E, Kato T, Ciuleanu TE, Dy GK, Parente B, O'Byrne KJ, Chu QS, Castro Junior G, Girard N, Snyder W, Tran Q, Kormany W, Houk B, Mehta B, Curioni-Fontecedro A. Hochmair MJ, et al. Among authors: curioni fontecedro a. Eur J Cancer. 2024 Sep;208:114204. doi: 10.1016/j.ejca.2024.114204. Epub 2024 Jul 5. Eur J Cancer. 2024. PMID: 39029295 Clinical Trial.
Lung Cancer in Switzerland.
Werner RS, Curioni-Fontecedro A, Mauti LA, Addeo A, Peters S, Frauenfelder T, Puhan MA, Haberecker M, Bubendorf L, Finazzi T, Guckenberger M, Cafarotti S, Geiser T, Opitz I; SAKK. Werner RS, et al. Among authors: curioni fontecedro a. J Thorac Oncol. 2024 Mar;19(3):385-394. doi: 10.1016/j.jtho.2023.12.005. J Thorac Oncol. 2024. PMID: 38453327 No abstract available.
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, Stahel RA. Homicsko K, et al. Among authors: curioni fontecedro a. J Immunother Cancer. 2023 Oct;11(10):e007585. doi: 10.1136/jitc-2023-007585. J Immunother Cancer. 2023. PMID: 37880184 Free PMC article.
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.
Hiltbrunner S, Cords L, Kasser S, Freiberger SN, Kreutzer S, Toussaint NC, Grob L, Opitz I, Messerli M, Zoche M, Soltermann A, Rechsteiner M, van den Broek M, Bodenmiller B, Curioni-Fontecedro A. Hiltbrunner S, et al. Among authors: curioni fontecedro a. Nat Commun. 2023 Aug 24;14(1):5154. doi: 10.1038/s41467-023-40745-5. Nat Commun. 2023. PMID: 37620318 Free PMC article.
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Opitz I, Guckenberger M, Früh M, Betticher DC, Ris HB, Stupp R, Rothschild SI, Bubendorf L, Pless M. König D, et al. Among authors: curioni fontecedro a. ESMO Open. 2023 Aug;8(4):101595. doi: 10.1016/j.esmoop.2023.101595. Epub 2023 Jul 11. ESMO Open. 2023. PMID: 37441877 Free PMC article.
86 results